Evidence map›Paper›PMID 38400943›Full record

ArticleObesity surgery2024

Effects of Preoperative Quadruple Therapy for Helicobacter pylori on Bariatric Surgery Metabolic Outcomes.

Albert Goday, Andrea Bagán, Anna Casajoana, Carme Serra, Manuel Pera, Montserrat Villatoro, Teresa Legido, Helena Julià, Elisenda Climent, Olga Castañer and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Obesity surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Albert GodayDepartment of Endocrinology and Nutrition, Hospital del Mar, 08003, Barcelona, Spain.
Andrea BagánDepartment of Medicine, Universitat Pompeu Fabra. Plaça de la Mercè, 10-12, E-08002, Barcelona, Spain.
Anna CasajoanaUnit of Gastrointestinal Surgery, Hospital del Mar, Institut de Recerca IMIM- Hospital del Mar, 08003, Barcelona, Spain.
Carme SerraDepartment of Endocrinology and Nutrition, Hospital del Mar, 08003, Barcelona, Spain.
Manuel PeraUnit of Gastrointestinal Surgery, Hospital del Mar, Institut de Recerca IMIM- Hospital del Mar, 08003, Barcelona, Spain.
Montserrat VillatoroDepartment of Endocrinology and Nutrition, Hospital del Mar, 08003, Barcelona, Spain.
Teresa LegidoNeuroscience Group, Hospital del Mar Medical Research Institute, 08003, Barcelona, Spain.
Helena JuliàDepartment of Endocrinology and Nutrition, Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, 08243, Barcelona, Spain.
Elisenda ClimentDepartment of Endocrinology and Nutrition, Hospital del Mar, 08003, Barcelona, Spain.
Olga CastañerDepartment of Endocrinology and Nutrition, Hospital del Mar, 08003, Barcelona, Spain.
Juana A Flores Le RouxDepartment of Endocrinology and Nutrition, Hospital del Mar, 08003, Barcelona, Spain.
Miguel OlanoDepartment of Endocrinology and Nutrition, Hospital del Mar, 08003, Barcelona, Spain.
Juan Pedro-BotetDepartment of Endocrinology and Nutrition, Hospital del Mar, 08003, Barcelona, Spain.
David BenaigesDepartment of Endocrinology and Nutrition, Hospital del Mar, 08003, Barcelona, Spain. dbenaiges@psmar.cat.ORCID 0000-0001-5411-364X
Hospital Del Mar · ESUniversitat Autònoma de Barcelona · ESBarcelona Biomedical Research Park · ESUniversitat Pompeu Fabra · ESAlthaia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the effects of Helicobacter pylori (HP) eradication with an omeprazole, clarithromycin, amoxicillin, and metronidazole (OCAM) regimen on the metabolic profile and weight loss 12 months after bariatric surgery (BS).

methodsRetrospective analysis of a prospective cohort of patients with morbid obesity undergoing BS. HP presence was tested preoperatively by gastric biopsy and treated with OCAM when positive. Short-term metabolic outcomes and weight loss were evaluated.

resultsHP infection was detected in 75 (45.7%) of the 164 patients included. OCAM effectiveness was 90.1%. HP-negative patients had a greater reduction in glucose levels at 3 (-14.6 ± 27.5 mg/dL HP-treated vs -22.0 ± 37.1 mg/dL HP-negative, p=0.045) and 6 months (-13.7 ± 29.4 mg/dL HP-treated vs -26.4 ± 42.6 mg/dL HP-negative, p= 0.021) and greater total weight loss (%TWL) at 6 (28.7 ± 6.7% HP-treated vs 30.45 ± 6.48% HP-negative, p= 0.04) and 12 months (32.21 ± 8.11% HP-treated vs 35.14 ± 8.63% HP-negative, p= 0.023).

conclusionsPreoperative treatment with OCAM has been associated to poorer glycemic and weight loss outcomes after BS. More research is needed on the influence of OCAM on gut microbiota, and in turn, the effect of the latter on metabolic and weight loss outcomes after BS.

Indexed as

Bariatric SurgeryHelicobacter InfectionsHelicobacter pyloriObesity, MorbidAmoxicillinAnti-Bacterial AgentsClarithromycinDrug Therapy, CombinationHumansMetronidazoleOmeprazoleProspective StudiesRetrospective StudiesWeight LossAmoxicillinAnti-Bacterial AgentsClarithromycinMetronidazoleOmeprazoleBariatric surgeryGastric bypassHelicobacter pyloriMorbid obesitySleeve gastrectomy

Identifiers

PMID38400943
PMCPMC11026217
OpenAlexW4392138371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.